ACADIA Pharmaceuticals Inc. (ACAD) Comparison with companies in other sectors?

ACADIA Pharmaceuticals Inc. has a share price of 167.36M. You can analyze ACADIA Pharmaceuticals Inc. (ACAD) competitors across different market sectors through stock heatmaps.

What are ACAD's NET and operating margins?

ACADIA Pharmaceuticals Inc. (ACAD) operating margin is around 0.24, and net profit margin is approximately 0.23 as of the latest reports.

In what way does ACAD's earnings per share (EPS) trend reflect its financial momentum?

ACADIA Pharmaceuticals Inc. (ACAD) EPS is 1.37 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for ACADIA Pharmaceuticals Inc. is 16.97, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for ACADIA Pharmaceuticals Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for ACADIA Pharmaceuticals Inc. like P/E which is 17.04, P/B which is 5.10, and PEG which is 23.34. Compare them with sector averages to evaluate if the stock is priced fairly.

ACADIA Pharmaceuticals Inc.

ACAD•NASDAQ

Healthcare

Biotechnology

$23.25

$0.20(0.87%)

Fundamental Analysis of ACADIA Pharmaceuticals Inc. (ACAD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.37

P/E Ratio

16.97

ROE

0.35%

Net Margin

0.23%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.89B

Shares OutstandingTotal number of shares issued

$167.36M

Book Value/ShareNet worth per share

$4.59

Revenue/ShareAnnual revenue per share

$5.97

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.37

Net MarginNet income as percentage of revenue

22.97%

Operating MarginOperating income as percentage of revenue

23.58%

ROEReturn on shareholders' equity

35.32%

ROAReturn on total assets

20.21%

ROCEReturn on capital employed

28.30%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.30

Cash/ShareCash and equivalents per share

$4.09

FCF YieldFree cash flow as percentage of market cap

1.28%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ACADFinancial Ratios Analysis details for ACAD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ACADSector Benchmarking details for ACAD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for ACADIA Pharmaceuticals Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of ACADIA Pharmaceuticals Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account ACADIA Pharmaceuticals Inc.'s unique business strengths and challenges.

Key Financial Metrics for ACADIA Pharmaceuticals Inc.

For ACADIA Pharmaceuticals Inc., essential financial indicators include EPS 1.37, PE 16.97, and ROE 0.35. These key ratios reveal insights into ACADIA Pharmaceuticals Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare ACADIA Pharmaceuticals Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of ACADIA Pharmaceuticals Inc.

Metrics like Net Margin 22.97% and ROA 20.21% shed light on how well ACADIA Pharmaceuticals Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether ACADIA Pharmaceuticals Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of ACADIA Pharmaceuticals Inc.

Using ratios such as P/B Ratio 5.10 and PEG Ratio 23.34, investors can assess whether ACADIA Pharmaceuticals Inc. is appropriately valued based on its financials and growth potential. These figures, combined with ACADIA Pharmaceuticals Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for ACADIA Pharmaceuticals Inc.

Financial health indicators, such as Debt/Equity Ratio 0.07 and Cash Flow $0.30, provide a snapshot of ACADIA Pharmaceuticals Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like ACADIA Pharmaceuticals Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for ACADIA Pharmaceuticals Inc.

Investing in ACADIA Pharmaceuticals Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at ACADIA Pharmaceuticals Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;